DISCOVER FINANCE

On October 19, 2026, shares of biotechnology company Disc Medicine surged 35% following its announcement of a successful phase 3 trial for bitopertin, its experimental treatment for a rare genetic condition that causes extreme sensitivity to sunlight. The results mark a significant turnaround for the company, as it was met with an FDA rejection earlier in the year. The disorder being targeted is called erythropoietic protoporphyria (EPP), which leads patients to accumulate h

As the global AI race charges on, SpaceX may be making a huge move that could propel it forward. The company is reportedly seeking a $40 billion financing package to purchase advanced AI chips from Nvidia. If pushed through, the deal would become one of the largest AI infrastructure financing arrangements in history, reflecting how major tech companies are increasingly turning to debt markets to finance their AI expansion. SpaceX is specifically targeting Nvidia’s advanced p

Pharmaceutical giant AstraZeneca just made a $2 billion equity investment in Summit Therapeutics, establishing its commitment to new and advanced cancer treatments and reflecting the increasing competition surrounding the oncology market. The investment focuses on ivonescimab, Summit’s experimental cancer drug that has garnered much attention for its potential to challenge existing immunotherapies. What differentiates Ivonescimab and makes it so appealing is its ability to t

On Friday, October 9, Wall Street continued advancing upwards as major U.S. stock indexes grew despite increasing concerns over high Treasury yields and persistent inflation. The S&P 500 gained approximately 0.6%, while the Dow Jones Industrial Average rose 0.8% and the Nasdaq Composite climbed 0.6%. It seems like there is a growing divergence between the stock and bond markets, as investors are reacting differently to the same economic uncertainties. Historically, rising Tr

Private credit has become one of Wall Street’s fastest growing industries. Companies obtain loans directly from investment firms like Blackstone and Apollo instead of borrowing from traditional banks. As of recently, regulators have begun questioning how much risk private credit has brought outside the traditional banking system. This past week, reports have revealed that the Federal Reserve Bank of New York has been examining banks like JPMorgan, Wells Fargo, Barclays, Morg

Artificial intelligence has already made its impact on sectors ranging from financial services to software development. Now, investors are betting it could revolutionize one of the most expensive and uncertain industries: pharmaceutical drug discovery. On October 8, 2026, Nvidia-backed biotechnology company Iambic Therapeutics announced its intent to launch an IPO, with a goal of raising up to $159.4 million. This potentially values the company at around $806 million. The co